Ben Ponvilawan: HCC Etiology’s Impact on Positive Results in the CARES-310 Trial

Ben Ponvilawan, Doctor of Medicine at UMKC Internal Medicine Residency Program, shared on X:

” Our correspondence is now available on The Lancet! Differences in HCC etiology may contribute to the positive result of camrelizumab plus rivoceranib in CARES-310 trial, in contrast to other IO+TKI trials.

Thank you Marc Roth, Saint Luke’s Cancer Institute for the support.”